Acute effects of lysergic acid diethylamide in healthy subjects

Biological Psychiatry

Volumn 78, Issue 8, 2015, Pages 544-553

  Schmid, Yasmin ^a   Enzler, Florian ^a   Gasser, Peter ^b   Grouzmann, Eric ^c   Preller, Katrin H ^d   Vollenweider, Franz X ^d   Brenneisen, Rudolf ^e   Müller, Felix ^f   Borgwardt, Stefan ^f   Liechti, Matthias E ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b Practice for Psychiatry and Psychotherapy   (Switzerland)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^d UNIVERSITY HOSPITAL OF PSYCHIATRY ZURICH   (Switzerland)

^e UNIVERSITY OF BERN   (Switzerland)

^f UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Adverse effects; Hormones; LSD; Prepulse inhibition; Subjective effects; Sympathomimetic effects

Indexed keywords

ADRENALIN; HYDROCORTISONE; LYSERGIDE; OXYTOCIN; PLACEBO; PROLACTIN; ADRENERGIC RECEPTOR STIMULATING AGENT; PSYCHEDELIC AGENT;

ADRENALIN BLOOD LEVEL; ADULT; ARTICLE; AUTONOMIC NERVOUS SYSTEM; BODY TEMPERATURE; CONSCIOUSNESS; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEPERSONALIZATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ELEVATED BLOOD PRESSURE; ENDOCRINE SYSTEM; FEMALE; HALLUCINATION; HAPPINESS; HEART RATE; HUMAN; HYDROCORTISONE BLOOD LEVEL; INTIMACY; MALE; NORMAL HUMAN; OUTCOME ASSESSMENT; OXYTOCIN BLOOD LEVEL; PREPULSE INHIBITION; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PSYCHOMETRY; PUPIL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STARTLE REFLEX; TRUST; VISUAL HALLUCINATION; WAKEFULNESS; WELLBEING; ANIMAL; DRUG EFFECTS; MIDDLE AGED; PSYCHOLOGY; PSYCHOTHERAPY; SENSORY GATING;

ADULT; ANIMALS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HALLUCINOGENS; HEALTHY VOLUNTEERS; HUMANS; LYSERGIC ACID DIETHYLAMIDE; MALE; MIDDLE AGED; PSYCHOTHERAPY; REFLEX, STARTLE; SENSORY GATING; SYMPATHOMIMETICS;

EID: 84941261969     PISSN: 00063223     EISSN: 18732402     Source Type: Journal    
DOI: 10.1016/j.biopsych.2014.11.015     Document Type: Article

References (91)

1. T. Passie, J.H. Halpern, D.O. Stichtenoth, H.M. Emrich, and A. Hintzen The pharmacology of lysergic acid diethylamide: A review CNS Neurosci Ther 14 2008 295 314
2. D.E. Nichols Hallucinogens Pharmacol Ther 101 2004 131 181
3. A. Hofmann How LSD originated J Psychedelic Drugs 11 1979 53 60
4. G.B. Koelle The pharmacology of mescaline and D-lysergic acid diethylamide (LSD) N Engl J Med 258 1958 25 32
5. N.A. Bercel, L.E. Travis, L.B. Olinger, and E. Dreikurs Model psychoses induced by LSD-25 in normals. I. Psychophysiological investigations, with special reference to the mechanism of the paranoid reaction AMA Arch Neurol Psychiatry 75 1956 588 611
6. T.S. Krebs, and P.O. Johansen Lysergic acid diethylamide (LSD) for alcoholism: Meta-analysis of randomized controlled trials J Psychopharmacol 26 2012 994 1002
7. C. Savage, and O.L. McCabe Residential psychedelic (LSD) therapy for narcotic addict: A controlled study Arch Gen Psychiatry 28 1973 808 814
8. R.A. Sewell, J.H. Halpern, and H.G. Pope Jr Response of cluster headache to psilocybin and LSD Neurology 66 2006 1920 1922
9. S. Grof, L.E. Goodman, W.A. Richards, and A.A. Kurland LSD-assisted psychotherapy in patients with terminal cancer Int Pharmacopsychiatry 8 1973 129 144
10. W.N. Pahnke, A.A. Kurland, L.E. Goodman, and W.A. Richards LSD-assisted psychotherapy with terminal cancer patients Curr Psychiatr Ther 9 1969 144 152
11. P. Gasser, D. Holstein, Y. Michel, R. Doblin, B. Yazar-Klosinski, T. Passie, and et al. Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases J Nerv Ment Dis 202 2014 513 520
12. European Monitoring Center for Drugs and Drug Addiction. European drug report 2014. Available at: www.emcdda.europa.eu. Accessed August 13, 2014.
13. Johnston LD, O Malley PM, Bachmann JG, Schulenberg JE, Miech RA (2014): Monitoring the Future: National Survey Results on Drug Use, 1975-2013: Volume 2, College Students and Adults Ages 19-55. Ann Arbor: Institute for Social Research, University of Michigan
14. Carhart-Harris RL, Kaelen M, Whalley MG, Bolstridge M, Feilding A, Nutt DJ (2014): LSD enhances suggestibility in healthy volunteers. Psychopharmacology. http://dx.doi/10.1007/s00213-014-3714-z
15. W.A. Stoll Lysergsäureäthylamid, ein Phantastikum aus der Mutterkorngruppe Schweiz Arch Neurol Psychiatr 60 1947 279 323
16. E. Rothlin Lysergic acid diethylamide and related substances Ann N Y Acad Sci 66 1957 668 676
17. S. Salvatore, and R.W. Hyde Progression of effects of lysergic acid diethylamide (LSD) AMA Arch Neurol Psychiatry 76 1956 50 59
18. L.E. Hollister, and A.M. Hartman Mescaline, lysergic acid diethylamide and psilocybin comparison of clinical syndromes, effects on color perception and biochemical measures Compr Psychiatry 3 1962 235 242
19. R.J. Strassman, C.R. Qualls, E.H. Uhlenhuth, and R. Kellner Dose-response study of N,N-dimethyltryptamine in humans. II. Subjective effects and preliminary results of a new rating scale Arch Gen Psychiatry 51 1994 98 108
20. J. Riba, A. Rodriguez-Fornells, and M.J. Barbanoj Effects of ayahuasca on sensory and sensorimotor gating in humans as measured by P50 suppression and prepulse inhibition of the startle reflex, respectively Psychopharmacology 165 2002 18 28
21. R.G. Dos Santos, M. Valle, J.C. Bouso, J.F. Nomdedeu, J. Rodriguez-Espinosa, E.H. McIlhenny, and et al. Autonomic, neuroendocrine, and immunological effects of ayahuasca: A comparative study with d-amphetamine J Clin Psychopharmacol 31 2011 717 726
22. E. Gouzoulis-Mayfrank, K. Heekeren, A. Neukirch, M. Stoll, C. Stock, M. Obradovic, and et al. Psychological effects of (S)-ketamine and N,N-dimethyltryptamine (DMT): A double-blind, cross-over study in healthy volunteers Pharmacopsychiatry 38 2005 301 311
23. J.H. Krystal, L.P. Karper, J.P. Seibyl, G.K. Freeman, R. Delaney, J.D. Bremner, and et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: Psychotomimetic, perceptual, cognitive, and neuroendocrine responses Arch Gen Psychiatry 51 1994 199 214
24. F.X. Vollenweider, K.L. Leenders, C. Scharfetter, A. Antonini, P. Maguire, J. Missimer, and et al. Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and [18F]fluorodeoxyglucose (FDG) Eur Neuropsychopharmacol 7 1997 9 24
25. R.L. Carhart-Harris, D. Erritzoe, T. Williams, J.M. Stone, L.J. Reed, A. Colasanti, and et al. Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin Proc Natl Acad Sci U S A 109 2012 2138 2143
26. F.X. Vollenweider, K.L. Leenders, C. Scharfetter, P. Maguire, O. Stadelmann, and J. Angst Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis Neuropsychopharmacology 16 1997 357 372
27. C.S. Grob, A.L. Danforth, G.S. Chopra, M. Hagerty, C.R. McKay, A.L. Halberstadt, and et al. Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer Arch Gen Psychiatry 68 2011 71 78
28. K. Kupferschmidt High hopes Science 345 2014 18 23
29. E. Studerus, A. Gamma, and F.X. Vollenweider Psychometric evaluation of the altered states of consciousness rating scale (OAV) PLoS One 5 2010 e12412
30. C.M. Hysek, L.D. Simmler, N. Schillinger, N. Meyer, Y. Schmid, M. Donzelli, and et al. Pharmacokinetic and pharmacodynamic effects of methylphenidate and MDMA administered alone and in combination Int J Neuropsychopharmacol 17 2014 371 381
31. W.R. Martin, J.W. Sloan, J.D. Sapira, and D.R. Jasinski Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man Clin Pharmacol Ther 12 1971 245 258
32. H.E. Hill, C.A. Haertzen, A.B. Wolbach Jr, and E.J. Miner The Addiction Research Center Inventory: Standardization of scales which evaluate subjective effects of morphine, amphetamine, pentobarbital, alcohol, LSD-25, pyrahexyl and chlorpromazine Psychopharmacologia 4 1963 167 183
33. E. Gouzoulis-Mayfrank, E. Habermeyer, L. Hermle, A. Steinmeyer, H. Kunert, and H. Sass Hallucinogenic drug induced states resemble acute endogenous psychoses: Results of an empirical study Eur Psychiatry 13 1998 399 406
34. M.A. Geyer, and F.X. Vollenweider Serotonin research: Contributions to understanding psychoses Trends Pharmacol Sci 29 2008 445 453
35. R.J. Langs, and H.L. Barr Lysergic acid diethylamide (LSD-25) and schizophrenic reactions: A comparative study J Nerv Ment Dis 147 1968 163 172
36. D.L. Braff, C. Grillon, and M.A. Geyer Gating and habituation of the startle reflex in schizophrenic patients Arch Gen Psychiatry 49 1992 206 215
37. V. Kumari, W. Soni, V.M. Mathew, and T. Sharma Prepulse inhibition of the startle response in men with schizophreni: Effects of age of onset of illness, symptoms, and medication Arch Gen Psychiatry 57 2000 609 614
38. K. Ludewig, M.A. Geyer, and F.X. Vollenweider Deficits in prepulse inhibition and habituation in never-medicated, first-episode schizophrenia Biol Psychiatry 54 2003 121 128
39. B.B. Quednow, I. Frommann, J. Berning, K.U. Kuhn, W. Maier, and M. Wagner Impaired sensorimotor gating of the acoustic startle response in the prodrome of schizophrenia Biol Psychiatry 64 2008 766 773
40. 2A receptor Psychopharmacology (Berl) 208 2010 179 189
41. T. Palenicek, Z. Hlinak, V. Bubenikova-Valesova, T. Novak, and J. Horacek Sex differences in the effects of N,N-diethyllysergamide (LSD) on behavioural activity and prepulse inhibition Prog Neuropsychopharmacol Biol Psychiatry 34 2010 588 596
42. A. Ouagazzal, A.J. Grottick, J. Moreau, and G.A. Higgins Effect of LSD on prepulse inhibition and spontaneous behavior in the rat: A pharmacological analysis and comparison between two rat strains Neuropsychopharmacology 25 2001 565 575
43. 2A receptors in the ventral pallidum Brain Res 761 1997 97 104
44. G.B. Varty, and G.A. Higgins Examination of drug-induced and isolation-induced disruptions of prepulse inhibition as models to screen antipsychotic drugs Psychopharmacology (Berl) 122 1995 15 26
45. 2 receptors in the effects of 5-MeO-DMT on locomotor activity and prepulse inhibition in rats Psychopharmacology (Berl) 189 2006 319 329
46. A.L. Halberstadt, and M.A. Geyer Serotonergic hallucinogens as translational models relevant to schizophrenia Int J Neuropsychopharmacol 16 2013 2165 2180
47. M. Johnson, W. Richards, and R. Griffiths Human hallucinogen research: Guidelines for safety J Psychopharmacol 22 2008 603 620
48. E. Gouzoulis-Mayfrank, F. Schneider, J. Friedrich, M. Spitzer, B. Thelen, and H. Sass Methodological issues of human experimental research with hallucinogens Pharmacopsychiatry 31 suppl 2 1998 114 118
49. A. Dittrich The standardized psychometric assessment of altered states of consciousness (ASCs) in humans Pharmacopsychiatry 31 suppl 2 1998 80 84
50. M. Farre, S. Abanades, P.N. Roset, A.M. Peiro, M. Torrens, B. O'Mathuna, and et al. Pharmacological interaction between 3,4-methylenedioxymethamphetamine (ecstasy) and paroxetine: Pharmacological effects and pharmacokinetics J Pharmacol Exp Ther 323 2007 954 962
51. W. Janke, and G. Debus Die Eigenschaftswörterliste Göttingen: Hogrefe 1978
52. C.M. Hysek, Y. Schmid, L.D. Simmler, G. Domes, M. Heinrichs, C. Eisenegger, and et al. MDMA enhances emotional empathy and prosocial behavior Soc Cogn Affect Neurosci 9 2014 1645 1652
53. H.D. Abraham, A.M. Aldridge, and P. Gogia The psychopharmacology of hallucinogens Neuropsychopharmacology 14 1996 285 298
54. F.X. Vollenweider, M.F. Vollenweider-Scherpenhuyzen, A. Babler, H. Vogel, and D. Hell Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action Neuroreport 9 1998 3897 3902
55. F. Hasler, U. Grimberg, M.A. Benz, T. Huber, and F.X. Vollenweider Acute psychological and physiological effects of psilocybin in healthy humans: A double-blind, placebo-controlled dose-effect study Psychopharmacology 172 2004 145 156
56. A.T. Shulgin Mescaline: The chemistry and pharmacology of its analogs Lloydia 36 1973 46 58
57. F.X. Vollenweider, and M. Kometer The neurobiology of psychedelic drugs: Implications for the treatment of mood disorders Nat Rev Neurosci 11 2010 642 651
58. C.M. Hysek, G. Domes, and M.E. Liechti MDMA enhances "mind reading" of positive emotions and impairs "mind reading" of negative emotions Psychopharmacology (Berl) 222 2012 293 302
59. R.R. Griffiths, W.A. Richards, U. McCann, and R. Jesse Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance Psychopharmacology (Berl) 187 2006 268 283
60. Y. Schmid, C.M. Hysek, L.D. Simmler, M.J. Crockett, B.B. Quednow, and M.E. Liechti Differential effects of MDMA and methylphenidate on social cognition J Psychopharmacol 28 2014 847 856
61. 1A receptor Neuropsychopharmacology 38 2013 2249 2259
62. 2 antagonist ketanserin in healthy humans Neuropsychopharmacology 23 2000 396 404
63. 2 receptor as a site of action for LSD and phenylisopropylamine hallucinogens Psychopharmacology (Berl) 94 1988 213 216
64. C.M. Hysek, L.D. Simmler, V. Nicola, N. Vischer, M. Donzelli, S. Krähenbühl, and et al. Duloxetine inhibits effects of MDMA ("ecstasy") in vitro and in humans in a randomized placebo-controlled laboratory study PLoS One 7 2012 e36476
65. M.E. Liechti, A. Gamma, and F.X. Vollenweider Gender differences in the subjective effects of MDMA Psychopharmacology (Berl) 154 2001 161 168
66. E. Studerus, A. Gamma, M. Kometer, and F.X. Vollenweider Prediction of psilocybin response in healthy volunteers PLoS One 7 2012 e30800
67. D.L. Braff, and M.A. Geyer Acute and chronic LSD effects on rat startle: Data supporting an LSD rat model of schizophrenia Biol Psychiatry 15 1980 909 916
68. F.X. Vollenweider, P.A. Csomor, B. Knappe, M.A. Geyer, and B.B. Quednow The effects of the preferential 5-HT2A agonist psilocybin on prepulse inhibition of startle in healthy human volunteers depend on interstimulus interval Neuropsychopharmacology 32 2007 1876 1887
69. E. Gouzoulis-Mayfrank, K. Heekeren, B. Thelen, H. Lindenblatt, K.A. Kovar, H. Sass, and et al. Effects of the hallucinogen psilocybin on habituation and prepulse inhibition of the startle reflex in humans Behav Pharmacol 9 1998 561 566
70. B.B. Quednow, M. Kometer, M.A. Geyer, and F.X. Vollenweider Psilocybin-induced deficits in automatic and controlled inhibition are attenuated by ketanserin in healthy human volunteers Neuropsychopharmacology 37 2012 630 640
71. K. Heekeren, A. Neukirch, J. Daumann, M. Stoll, M. Obradovic, K.A. Kovar, and et al. Prepulse inhibition of the startle reflex and its attentional modulation in the human S-ketamine and N,N-dimethyltryptamine (DMT) models of psychosis J Psychopharmacol 21 2007 312 320
72. J. Gonzalez-Maeso, R.L. Ang, T. Yuen, P. Chan, N.V. Weisstaub, J.F. Lopez-Gimenez, and et al. Identification of a serotonin/glutamate receptor complex implicated in psychosis Nature 452 2008 93 97
73. B.B. Quednow, A. Schmechtig, U. Ettinger, N. Petrovsky, D.A. Collier, F.X. Vollenweider, and et al. Sensorimotor gating depends on polymorphisms of the serotonin-2A receptor and catechol-O-methyltransferase, but not on neuregulin-1 Arg38Gln genotype: A replication study Biol Psychiatry 66 2009 614 620
74. C. Kornetsky Relation of physiological and psychological effects of lysergic acid diethylamide AMA Arch Neurol Psychiatry 77 1957 657 658
75. A. Dimascio, M. Greenblatt, and R.W. Hyde A study of the effects of L.S.D.: Physiologic and psychological changes and their interrelations Am J Psychiatry 114 1957 309 317
76. L. Sokoloff, S. Perlin, C. Kornetsky, and S.S. Kety The effects of D-lysergic acid diethylamide on cerebral circulation and over-all metabolism Ann N Y Acad Sci 66 1957 468 477
77. R.E. Belleville, H.F. Fraser, H. Isbell, A. Wikler, and C.R. Logan Studies on lysergic acid diethylamide (LSD-25): I. Effects in former morphine addicts and development of tolerance during chronic intoxication AMA Arch Neurol Psychiatry 76 1956 468 478
78. G.R. Forrer, and R.D. Goldner Experimental physiological studies with lysergic acid diethylamide (LSD-25) AMA Arch Neurol Psychiatry 65 1951 581 588
79. C.M. Hysek, L.D. Simmler, M. Ineichen, E. Grouzmann, M.C. Hoener, R. Brenneisen, and et al. The norepinephrine transporter inhibitor reboxetine reduces stimulant effects of MDMA ("ecstasy") in humans Clin Pharmacol Ther 90 2011 246 255
80. A. Horita, and J.M. Dille Pyretogenic effect of lysergic acid diethylamide Science 120 1954 1100 1101
81. J.C. Klock, U. Boerner, and C.E. Becker Coma, hyperthermia, and bleeding associated with massive LSD overdose, a report of eight cases Clin Toxicol 8 1975 191 203
82. H. Isbell Comparison of the reactions induced by psilocybin and LSD-25 in man Psychopharmacologia 1 1959 29 38
83. E. Gouzoulis-Mayfrank, B. Thelen, E. Habermeyer, H.J. Kunert, K.A. Kovar, H. Lindenblatt, and et al. Psychopathological, neuroendocrine and autonomic effects of 3,4-methylenedioxyethylamphetamine (MDE), psilocybin and d-methamphetamine in healthy volunteers: Results of an experimental double blind placebo controlled study Psychopharmacology 142 1999 41 50
84. R.J. Strassman, and C.R. Qualls Dose-response study of N,N-dimethyltryptamine in humans. I. Neuroendocrine, autonomic, and cardiovascular effects Arch Gen Psychiatry 51 1994 85 97
85. 1 dopamine receptors Psychopharmacology (Berl) 118 1995 401 409
86. 2 dopaminergic receptors and it potentiates dopamine-mediated prolactin secretion in lactotrophs in vitro Life Sci 63 1998 215 222
87. H.Y. Meltzer, R.G. Fessler, M. Simonovic, J. Doherty, and V.S. Fang Lysergic acid diethylamide: Evidence for stimulation of pituitary dopamine receptors Psychopharmacology (Berl) 54 1977 39 44
88. D.K. Sommers, M. van Wyk, and J.R. Snyman Dexfenfluramine-induced prolactin release as an index of central synaptosomal 5-hydroxytryptamine during treatment with fluoxetine Eur J Clin Pharmacol 46 1994 441 444
89. E. Seifritz, P. Baumann, M.J. Muller, O. Annen, M. Amey, U. Hemmeter, and et al. Neuroendocrine effects of a 20-mg citalopram infusion in healthy males. A placebo-controlled evaluation of citalopram as 5-HT function probe Neuropsychopharmacology 14 1996 253 263
90. J.C. Callaway, D.J. McKenna, C.S. Grob, G.S. Brito, L.P. Raymon, R.E. Poland, and et al. Pharmacokinetics of Hoasca alkaloids in healthy humans J Ethnopharmacol 65 1999 243 256
91. J. Seibert, C.M. Hysek, C.A. Penno, Y. Schmid, D.V. Kratschmar, M.E. Liechti, and et al. Acute effects of 3,4-methylenedioxymethamphetamine and methylphenidate on circulating steroid levels in healthy subjects Neuroendocrinology 100 2014 17 25